Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.58 |
| ▸ | SCN1A | P35498 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.58 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9614099 | 0.94 | CYP2D6 (0.57) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL4305 | 0.90 | CYP2D6 (0.63) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| Sulfuric Acid SCHEMBL19100311 | 0.88 | KDM4E (0.66) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL669873 | 0.86 | CYP2D6 (0.64) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL22862890 | 0.84 | KDM4E (0.66) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL15239796 | 0.82 | KDM4E (0.64) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL4278098 | 0.81 | CYP2D6 (0.65) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| Sulfuric Acid SCHEMBL9614123 | 0.81 | KDM4E (0.67) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL2150774 | 0.80 | KDM4E (0.61) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 | |
| SCHEMBL789401 | 0.80 | KDM4E (0.59) | CYP2D6KDM4EALDH1A1SLC22A1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048071-A1 | 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS | Cadrenal Therapeutics, Inc. | 2026-02-19 | — | — | US | disclosed |
| EP-4615432-A2 | 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS | Veralox Therapeutics Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024103023-A2 | 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS | VERALOX THERAPEUTICS (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | CHILDRENS MEDICAL CENTER (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-18 | — | — | US | disclosed |
| WO-2014160811-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20110086878-A1 | Treatments for Neuropathy | NIH-DEITR | 2011-04-14 | — | — | US | disclosed |
| US-7863295-B2 | Treatments for neuropathy | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2240177-A2 | TREATMENTS FOR NEUROPATHY | Children's Medical Center Corporation (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20090297478-A1 | Methods and Compositions for the Treatment of Lupus Using Clofarabine | WOOD CHRISTOPHER B | 2009-12-03 | — | — | US | disclosed |
| WO-2009102570-A2 | TREATMENTS FOR NEUROPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NIH-DEITR | 2009-08-13 | — | — | US | disclosed |
| EP-1551386-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LUPUS USING CLOFARABINE | BIOENVISION INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20060135463-A1 | Methods and compositions for the treatment of lupus using clofarabine | WOOD CHRISTOPHER B | 2006-06-22 | — | — | US | disclosed |
| WO-2006007312-A2 | CO-ADMINISTRATION OF DEHYDROEPIANDROSTERONE (DHEA) CONGENER WITH PHARMACEUTICALLY ACTIVE AGENTS FOR TREATING INFLAMMATION | INFLABLOC PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060004076-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | INFLABLOC PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| EP-1551386-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LUPUS USING CLOFARABINE | Bioenvision, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004028463-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LUPUS USING CLOFARABINE | BIOENVISION, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004076-A1 | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | CYP17A1, CYP21A2, SHBG | CYP2D6 81/4885KDM4E 3586/4885ALDH1A1 236/4885 |
| US-20090297478-A1 | Methods and Compositions for the Treatment of Lupus Using Clofarabine | SSB, BCL9, IL2 | CYP2D6 1126/4885KDM4E 1933/4885ALDH1A1 1996/4885 |
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | CYP2D6 3450/4885KDM4E 4167/4885ALDH1A1 358/4885 |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | CYP2D6 3450/4885KDM4E 4167/4885ALDH1A1 358/4885 |
| US-20060135463-A1 | Methods and compositions for the treatment of lupus using clofarabine | SSB, BCL9, IL2 | CYP2D6 1126/4885KDM4E 1933/4885ALDH1A1 1996/4885 |
| US-20260048071-A1 | 12-LIPOXYGENASE INHIBITORS FOR THE TREATMENT OF LUPUS | ALOX12, ALOX5, ALOX15 | CYP2D6 87/4885KDM4E 1329/4885ALDH1A1 613/4885 |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | PMP22, GAP43, NGF | CYP2D6 4821/4885KDM4E 2932/4885ALDH1A1 3005/4885 |
| US-20110086878-A1 | Treatments for Neuropathy | NGF, BDNF, NTRK2 | CYP2D6 3450/4885KDM4E 4167/4885ALDH1A1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.